Semaglutide vs. Tirzepatide and the Tradeoffs That Matter

Key Takeaways

The core difference is mechanism. Semaglutide (Ozempic, Wegovy) mimics one gut hormone, GLP-1. Tirzepatide (Mounjaro, Zepbound) mimics GLP-1 and a second hormone, GIP.
In the only trial that put them head to head, tirzepatide produced more weight loss, 20.2% of body weight versus 13.7% at 72 weeks. That trial was funded by tirzepatide’s maker, which doesn’t make the result false, but it’s worth knowing before treating the gap as neutral fact.
Semaglutide carries an FDA-approved claim for reducing heart attack and stroke risk, built on a large placebo-controlled trial in people who already have heart disease. Tirzepatide’s newest heart trial compared it to another drug instead of a placebo and showed it holds up, not that it wins.
Tirzepatide’s weight-loss version costs more on paper than semaglutide’s, but insurance coverage tracks your diagnosis more than your drug choice.

Ask about semaglutide vs. tirzepatide and the fast answer is tirzepatide. It won the one trial that tested both drugs in the same people, at the same time, on the same weight loss goal. That trial had a sponsor with a stake in the outcome, and it never tested the comparison that matters most to some people, established heart disease. It said nothing about price or access either. Semaglutide and tirzepatide work differently, perform differently, and cost differently, and which tradeoff matters most depends on what you’re optimizing for.

What’s different between semaglutide and tirzepatide

Semaglutide, sold as Ozempic for diabetes and Wegovy for weight loss, mimics a gut hormone called GLP-1 (glucagon-like peptide-1). GLP-1 slows how fast your stomach empties, tells your brain you’re full, and triggers insulin production when you eat.

Tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss, does the same GLP-1 job and adds a second one. It also mimics GIP (glucose-dependent insulinotropic polypeptide), a hormone that, alongside GLP-1, plays its own role in insulin release and fat metabolism.

According to Cleveland Clinic, tirzepatide engages the GIP receptor especially closely, while activating the GLP-1 receptor in a way that produces less of the receptor desensitization seen with GLP-1-only drugs. In plain terms, two hormone pathways working together appear to blunt appetite and improve insulin sensitivity more than one pathway alone.

Both drugs are once-weekly injections you give yourself, starting at a low dose and increasing every few weeks to the dose you tolerate. Neither one is a pill in its FDA-approved weight-loss form.

Weight loss, semaglutide vs. tirzepatide

Most of what gets said about these two drugs comes from separate trials run years apart, on different people, which makes side-by-side numbers unreliable. SURMOUNT-5, published in the New England Journal of Medicine, fixed that by randomly assigning 751 adults with obesity, none of whom had diabetes, to the highest dose they could tolerate of either drug and following them for 72 weeks.

The result favored tirzepatide clearly. People on tirzepatide lost 20.2% of their body weight on average, compared with 13.7% on semaglutide, a gap of about 7.9 kilograms (22.8 kg versus 15.0 kg). Waist circumference dropped 18.4 cm on tirzepatide versus 13.0 cm on semaglutide. Nearly a third of the tirzepatide group (31.6%) lost at least a quarter of their body weight, compared with 16.1% on semaglutide.

Two things temper that gap. First, the trial was funded by Eli Lilly, which makes tirzepatide, a detail the trial’s published summary confirms directly. An industry-funded head-to-head result in the sponsor’s favor isn’t automatically wrong, this is a large, randomized, peer-reviewed trial, but it’s a reason to want independent replication before treating the size of the gap as settled. Second, the trial ran in adults without diabetes seeking weight loss specifically. It doesn’t tell you how the drugs compare for blood sugar control in people who do have diabetes, where both were originally approved.

What the side effects look like, and who tolerates which better

Nausea, vomiting, diarrhea, and constipation show up with both drugs, most often while the dose is still being increased, and side effects are the top reason people quit either medication. During the trial, more people stopped semaglutide over side effects than stopped tirzepatide. 8.0% of the semaglutide group discontinued the drug for any reason, versus 6.1% of the tirzepatide group, and gastrointestinal-specific discontinuations ran 5.6% on semaglutide versus 2.7% on tirzepatide.

That doesn’t mean tirzepatide is gentler for everyone. Individual response varies enough that some people tolerate semaglutide better and switch away from tirzepatide, not the reverse. If nausea or appetite loss is severe enough to cut your intake sharply, the nutrient gaps that follow are the same regardless of which drug caused them, and a short list of supplements covers the deficiencies most worth watching for. Rapid weight loss from either drug can also change how your face looks before it changes anything else, a real and mechanistically understood effect known as Ozempic face.

Does either one protect your heart

This is where the comparison stops being close, because the two drugs have been tested against different questions.

Semaglutide has an FDA-approved indication specifically for reducing cardiovascular risk, added in March 2024 based on the SELECT trial, which followed 17,604 adults with obesity or overweight and existing heart disease, no diabetes, for about three years against a placebo. Semaglutide cut major cardiac events by 20%, heart attacks by 28%, and all-cause death by 19%. Yale cardiologist Dr. Harlan Krumholz called it “a major breakthrough,” and the label change means a doctor can prescribe semaglutide specifically to protect a patient’s heart, not only to help them lose weight.

Tirzepatide’s most relevant heart trial, SURPASS-CVOT, published in December 2025, asked a different question entirely. It compared tirzepatide against another diabetes drug, dulaglutide, in 13,299 people who already had type 2 diabetes and cardiovascular disease, not against a placebo, and not in people without diabetes. Tirzepatide matched dulaglutide’s heart protection (cardiovascular death, heart attack, or stroke occurred in 12.2% of the tirzepatide group versus 13.1% on dulaglutide).

Statistically, that counts as non-inferior, meaning tirzepatide didn’t do worse than dulaglutide, not that it did better. Nothing here proves tirzepatide beats a placebo on heart outcomes, and as of this writing it doesn’t carry semaglutide’s cardiovascular-risk-reduction label. If heart protection specifically is what you’re weighing this decision on, semaglutide currently has the stronger, more directly relevant evidence.

What they cost, and what insurance will cover

Neither drug is cheap without coverage. As of mid-2025 retail pricing tracked by SingleCare, Wegovy (semaglutide, weight loss) listed around $1,820 a month, more than Zepbound (tirzepatide, weight loss) at roughly $1,519. On the diabetes side, Mounjaro ran about $1,493 against Ozempic’s $1,384. Prices move often enough that these are a snapshot, not a guarantee of what you’ll see today, and manufacturer savings cards or a pharmacy discount card can cut the cash price by hundreds of dollars a month regardless of which drug you’re on.

Insurance coverage depends far more on your diagnosis than on your drug choice. Plans are consistently more likely to cover either medication when it’s prescribed for type 2 diabetes than when it’s prescribed for weight loss alone, even though both drugs are FDA-approved for weight loss under their Wegovy and Zepbound names. If cost is the deciding factor, the conversation worth having with your doctor and insurer is about your diagnosis and what your specific plan will pay for, not just which of the two drugs to pick.

Is either one hard to get right now

Not anymore, at least not for the brand-name products. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, according to Pharmacy Times. Both drugs had been on the shortage list since early 2022, when demand surged past what manufacturers could produce.

What’s changing now is the compounded, off-brand version of both drugs. The same shortage resolution that restored supply also removed the legal basis pharmacies had for compounding copies of either medication, and in April 2026 the FDA proposed formally excluding semaglutide and tirzepatide from the list of drugs outsourcing pharmacies can compound from bulk ingredients, with a public comment period running through June 29, 2026. If you’ve been getting a compounded version of either drug because the brand-name product wasn’t available, that reason no longer applies, and the compounded pathway itself is narrowing.

None of these tradeoffs points to one obvious winner. Weight loss and tolerability favor tirzepatide, heart protection currently favors semaglutide, and cost depends on which version you’re comparing and what your plan pays for. Your own health history, not a head-to-head trial, is what should settle which one you bring up with your doctor.